New hope for bladder cancer patients who failed standard therapy

NCT ID NCT06351904

Recruiting now Disease control Sponsor: Ractigen Therapeutics. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 25 times

Summary

This early-stage study tests a new drug called RAG-01 in about 72 adults with a type of bladder cancer that has not improved after standard BCG treatment. The main goals are to check the drug's safety and find the best dose. Researchers will also look for early signs that the drug is working.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

GenesisCare North Shore
RECRUITING

St Leonards, New South Wales, 2065, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Peninsula & South Eastern Haematology and Oncology Group
RECRUITING

Melbourne, Victoria, 3199, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Royal Melbourne Hospital
RECRUITING

Melbourne, Victoria, 3050, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)